Home | Welcome to Contract Pharma   
Last Updated Tuesday, May 26 2015


Financial Report: Pfizer

Published April 30, 2013

1Q Revenues: $13.5 billion (-9%)
1Q Earnings: $2.8 billion (+53%)
Comments: Primary Care sales were down 21% to $3.2 billion impacted a 55% drop in Lipitor revenues and loss of exclusivity and near-term expiration of co-promotion agreements for Aricept and Spiriva. These declines were partially offset by Lyrica sales, up 12% to $1.1 billion. Oncology sales were up 31% to $372 million, driven by recent launches Inlyta and Xalkori in several major markets. Specialty Care sales were down 11% to $3.2 billion. Buying patterns for Prevnar 13 hurt revenues. Emerging Markets sales were up 6% to $2.4 billion. Established Product sales were down 15% to $2.4 billion. Consumer Healthcare sales were up 12% to $811 million. R&D Expenses were $1.7 billion, down 3%. Earnings reflect divested interest in Zoetis.

blog comments powered by Disqus

Receive free Contract Pharma Direct emails
Sign up now to receive the weekly newsletter, and more!

Enter your email address:
Follow Contract Pharma On